Patents Assigned to University of Washington through its Center for Commercialization
  • Patent number: 11248028
    Abstract: The present invention provides recombinant adenoviral compositions and methods for their use in treating disorders associated with epithelial tissues.
    Type: Grant
    Filed: March 2, 2020
    Date of Patent: February 15, 2022
    Assignee: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
    Inventors: Andre Lieber, Hongjie Wang
  • Publication number: 20220040275
    Abstract: The compositions described herein include an epitope of a peptide that may elicit an immune response in a subject following administration. The compositions may comprise nucleic acids. The compositions may comprise peptides. The methods described herein include administering a composition comprising an epitope of a peptide to a subject in need thereof.
    Type: Application
    Filed: October 20, 2021
    Publication date: February 10, 2022
    Applicant: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
    Inventors: Mary L. DISIS, Denise Cecil, Meredith Slota
  • Patent number: 11242562
    Abstract: Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: February 8, 2022
    Assignee: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
    Inventors: Jesse Salk, Lawrence A. Loeb, Michael Schmitt
  • Patent number: 11221336
    Abstract: The present disclosure provides encoded chromophoric polymer particles that are capable of, for example, optical and/or biomolecular encoding of analytes. The present disclosure also provides suspensions comprising a plurality of encoded chromophoric polymer particles. The present disclosure also provides methods of using the encoded chromophoric polymer particles and systems for performing multiplex analysis with encoded chromophoric polymer particles.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: January 11, 2022
    Assignee: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
    Inventors: Daniel T. Chiu, Changfeng Wu, Jiangbo Yu
  • Patent number: 11220700
    Abstract: This invention relates to a process for producing lipids and amino acids from a gaseous substrate comprising methane and oxygen. The process uses a culture of a methanotrophic microorganism in a liquid nutrient medium. The methanotrophic microorganism can be a Methylomicrobium bacterium and more specifically Methylomicrobium buryatense 5GB1. The lipid products can be in the cellular membrane of the methanotroph and can be extracted in a separate extraction zone.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: January 11, 2022
    Assignees: LanzaTech New Zealand Limited, UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION, ALLIANCE FOR SUSTAINABLE ENERGY, LLC
    Inventors: Mary Elizabeth Lidstrom, Marina Georgievna Kalyuzhnaya, Derek Wayne Griffin, Nicholas Bourdakos, Philip Thomas Pienkos, Lieve Maria Louisa Laurens
  • Patent number: 11219896
    Abstract: Devices, systems and apparatuses for the discretization and manipulation of sample volumes are provided. Related methods are also provided.
    Type: Grant
    Filed: June 25, 2014
    Date of Patent: January 11, 2022
    Assignee: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
    Inventors: Daniel T. Chiu, Thomas Schneider, Jason E. Kreutz
  • Patent number: 11198907
    Abstract: Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: December 14, 2021
    Assignee: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
    Inventors: Jesse Salk, Lawrence A. Loeb, Michael Schmitt
  • Patent number: 11185578
    Abstract: The compositions described herein include an epitope of a peptide that may elicit an immune response in a subject following administration. The compositions may comprise nucleic acids. The compositions may comprise peptides. The methods described herein include administering a composition comprising an epitope of a peptide to a subject in need thereof.
    Type: Grant
    Filed: June 25, 2021
    Date of Patent: November 30, 2021
    Assignee: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
    Inventors: Mary L. Disis, Denise Cecil, Meredith Slota
  • Patent number: 11185583
    Abstract: An immunogenic fusion protein for use as a mucosal vaccine is provided, which includes: i) one or more FcyR1-binding domains; ii) one or more antigens from one or more infectious disease organisms; and iii) one or more FcRn-binding domains.
    Type: Grant
    Filed: February 11, 2015
    Date of Patent: November 30, 2021
    Assignees: Albany Medical College, University of Washington through its Center for Commercialization
    Inventors: Edmund J. Gosselin, Deborah Fuller
  • Publication number: 20210346480
    Abstract: The compositions described herein include an epitope of a peptide that may elicit an immune response in a subject following administration. The compositions may comprise nucleic acids. The compositions may comprise peptides. The methods described herein include administering a composition comprising an epitope of a peptide to a subject in need thereof.
    Type: Application
    Filed: June 25, 2021
    Publication date: November 11, 2021
    Applicant: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
    Inventors: Mary L. DISIS, Denise CECIL, Meredith SLOTA
  • Patent number: 11167025
    Abstract: The invention provides methods and compositions for eliciting broad immune responses. The methods employ nucleic acid vaccines that encodes highly conserved elements from a virus.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: November 9, 2021
    Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
    Inventors: George Pavlakis, Barbara Felber, James Mullins
  • Publication number: 20210339008
    Abstract: An adaptive system for efficient and long-range wireless power delivery using magnetically coupled resonators responds to changes in a dynamic environment, and maintains high efficiency over a narrow or fixed frequency range. The system uses adaptive impedance matching to maintain high efficiency. The wireless power transfer system includes a drive inductor coupled to a high-Q transmitter coil, and a load inductor coupled to a high-Q receiver coil. The transmitter coil and receiver coil for a magnetically coupled resonator. A first matching network is (i) operably coupled to the drive inductor and configured to selectively adjust the impedance between the drive inductor and the transmitter coil, or (ii) is operably coupled to the load inductor and configured to selectively adjust the impedance between the load inductor and the receiver coil.
    Type: Application
    Filed: July 15, 2021
    Publication date: November 4, 2021
    Applicant: University of Washington through its Center for Commercialization
    Inventors: Joshua R. Smith, Benjamin H. Waters, Scott Wisdom, Alanson P. Sample
  • Patent number: 11155851
    Abstract: Methods are provided for detecting enzymatic activity of various lysosomal storage enzymes using substrates that include: a sugar moiety; a linker moiety allowing the conjugation of sugar moiety with the remaining structure of the substrate; and two or more fatty acid chains or derivatives thereof at least one of which is sufficiently structured to provide improved solubility in aqueous or organic solvent systems. Also provided are internal standards, and inhibitors for use in detecting or reducing enzymatic activity using the inventive substrates.
    Type: Grant
    Filed: June 21, 2016
    Date of Patent: October 26, 2021
    Assignees: University of Washington through its Center for Commercialization, PerkinElmer Health Sciences, Inc.
    Inventors: Alexander Cherkassky, Jason Coumoyer, Michael Gelb
  • Patent number: 11155869
    Abstract: Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: October 26, 2021
    Assignee: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
    Inventors: Jesse Salk, Lawrence A. Loeb, Michael Schmitt
  • Patent number: 11130996
    Abstract: Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: September 28, 2021
    Assignee: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
    Inventors: Jesse Salk, Lawrence A. Loeb, Michael Schmitt
  • Patent number: 11118225
    Abstract: Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand.
    Type: Grant
    Filed: August 31, 2020
    Date of Patent: September 14, 2021
    Assignee: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
    Inventors: Jesse Salk, Lawrence A. Loeb, Michael Schmitt
  • Patent number: 11105820
    Abstract: Photonic devices, systems, and methods for detecting an analyte in a biological solution (e.g., whole blood) are provided. Representative photonic devices are optical ring resonators having nanoscale features and micron-sized diameters. Due to the compact size of these devices, many resonators can be disposed on a single substrate and tested simultaneously as a sample is passed over the devices. Typical analytes include blood cells, antibodies, and pathogens, as well as compounds indicative of the presence of blood cells or pathogens (e.g., serology). In certain embodiments, blood type can be determined through photonic sensing using a combination of direct detection of blood cells and serology. By combining the detection signals of multiple devices, the type of blood can be determined.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: August 31, 2021
    Assignees: University of Washington through its Center for Commercialization, Bloodworks
    Inventors: Daniel M. Ratner, Jill M. Johnsen, James T. Kirk, José A. López, Norman D. Brault, Shaoyi Jiang
  • Patent number: 11098359
    Abstract: Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: August 24, 2021
    Assignee: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
    Inventors: Jesse Salk, Lawrence A. Loeb, Michael Schmitt
  • Patent number: 11096604
    Abstract: Methods, computing devices, and computer-readable medium are described herein related to producing detection signals configured to induce an excited state of an object. A computing device may receive reflection signals, where the reflection signals correspond to at least one detection signals reflected from the object. Based on the received reflection signals, a presence of the object in the excited state may be determined. Further, an output device may provide an indication of the presence of the object in the excited state.
    Type: Grant
    Filed: November 1, 2018
    Date of Patent: August 24, 2021
    Assignee: University of Washington through its Center for Commercialization
    Inventors: Michael R. Bailey, Wei Lu, Oleg A. Sapozhnikov, Bryan Cunitz
  • Patent number: 11090481
    Abstract: An adaptive system for efficient and long-range wireless power delivery using magnetically coupled resonators responds to changes in a dynamic environment, and maintains high efficiency over a narrow or fixed frequency range. The system uses adaptive impedance matching to maintain high efficiency. The wireless power transfer system includes a drive inductor coupled to a high-Q transmitter coil, and a load inductor coupled to a high-Q receiver coil. The transmitter coil and receiver coil for a magnetically coupled resonator. A first matching network is (i) operably coupled to the drive inductor and configured to selectively adjust the impedance between the drive inductor and the transmitter coil, or (ii) is operably coupled to the load inductor and configured to selectively adjust the impedance between the load inductor and the receiver coil.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: August 17, 2021
    Assignee: University of Washington through its Center for Commercialization
    Inventors: Joshua R. Smith, Benjamin H. Waters, Scott Wisdom, Alanson P. Sample